Synthaverse

Synthaverse EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synthaverse (SVE.WA) as of Oct 18, 2026 is -20.58 M PLN. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 17.90 M PLN — a change of -214.93% (lower).

EBITDA

-20.58 MPLN

YoY

-214.93%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synthaverse is 2025 -20.58 M PLN. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synthaverse was 2024 17.90 M PLN. It decreases by -214.93% lower compared to the previous year.

The Synthaverse EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-35.44 M PLN
Jan 1, 2019
5.72 M PLN
Jan 1, 2020
8.51 M PLN
Jan 1, 2021
9.82 M PLN
Jan 1, 2022
12.76 M PLN
Jan 1, 2023
12.39 M PLN
Jan 1, 2024
17.90 M PLN
Jan 1, 2025
-20.58 M PLN
The Synthaverse EBITDA history
YEAREBITDAYoY
-20.58 MPLN-214.93%
17.90 MPLN+44.48%
12.39 MPLN-2.90%
12.76 MPLN+29.93%
9.82 MPLN+15.47%
8.51 MPLN+48.76%
5.72 MPLN-116.13%
-35.44 MPLN-830.10%
4.85 MPLN-117.47%
-27.79 MPLN-16.42%
-33.25 MPLN-1,197.26%
3.03 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Synthaverse Stock analysis

What does Synthaverse do? Biomed Lublin is a Polish company that has been active in the production of serums and vaccines since 1950. It has grown to become a leading producer of biological substances and medical devices in Eastern Europe. The company was originally a state institution for the development of animal vaccines but was privatized after the political changes in the late 1980s. Since 2002, it has been listed on the Warsaw Stock Exchange and has expanded its focus. Biomed Lublin operates in four main areas: veterinary medicine, human medicine, diagnostics, and laboratory equipment. It has a strong reputation in the veterinary medicine field, offering vaccines and diagnostics for livestock and pets. The company is also involved in human medicine, producing vaccines and diagnostics exclusively in Poland. In the diagnostics field, Biomed Lublin has developed and manufactured a variety of test kits used in medical diagnostics. It also offers laboratory equipment such as microscopes, pipettes, and centrifuges for medical and biological testing in hospitals and laboratories. Overall, Biomed Lublin aims to continue expanding its presence in the biotech industry in Eastern Europe and providing high-quality and effective diagnostic and therapeutic solutions to improve the health of both humans and animals. Synthaverse is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Synthaverse stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synthaverse is -20.58 M PLN in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Synthaverse changed from 17.90 M PLN to -20.58 M PLN, representing a -214.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Synthaverse since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Synthaverse historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Synthaverse

All Key Metrics — Synthaverse